In our clinical trials of GPC3 peptide vaccine, we successfully established multiple types of GPC3 peptide-specific CTL clones derived from the peripheral blood and cancer tissue of vaccinated patients (34, 38, 48). The gene discussed is GPC3; the disease is cancer.